59 citations
,
September 2021 in “Journal of Allergy and Clinical Immunology” Netherton syndrome has two subtypes with shared immune traits but different allergic and immune responses, suggesting targeted treatments.
9 citations
,
May 2023 in “Stem Cell Research & Therapy” Stem cell treatment from umbilical cords reduces symptoms of atopic dermatitis and may help hair growth.
January 2026 in “Microorganisms” Bifidobacterium animalis subsp. lactis J12 helps reduce atopic dermatitis symptoms.
August 2025 in “JEADV Clinical Practice” Dupilumab successfully treated a woman's alopecia areata and bullous pemphigoid, leading to full hair regrowth and symptom resolution.
41 citations
,
December 2019 in “Science Translational Medicine” Anti-EGFR therapy can cause skin issues, but FGF7 treatment might help.
16 citations
,
June 2018 in “JAAD case reports” A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
4 citations
,
January 2023 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Biologics, especially Dupilumab, are effective and safe for treating severe childhood eczema.
June 2024 in “British Journal of Dermatology” Dupilumab can both cause and treat alopecia areata, with many patients experiencing hair regrowth.
April 2023 in “Journal of Investigative Dermatology” Chronic graft-versus-host disease in the skin shows strong Th1 immune response and unique barrier issues.
55 citations
,
April 2015 in “BMC medicine” Stem Cell Educator therapy helps regrow hair and improve life quality in alopecia areata patients.
3 citations
,
January 2019 in “Skin Appendage Disorders” People with alopecia areata may also have allergic rhinitis and should be checked for respiratory allergies.
2 citations
,
May 2025 in “Journal of Clinical Medicine” Upadacitinib is safe and effective for treating alopecia areata and atopic dermatitis in children.
1 citations
,
July 2025 in “Diagnostics” Dupilumab users have a higher risk of developing alopecia areata.
1 citations
,
May 2017 in “InTech eBooks” New treatments focusing on immune pathways show promise for stubborn hair loss.
February 2026 in “Journal of Allergy and Clinical Immunology” Alopecia areata involves immune system issues and specific cell types that disrupt hair growth, leading to hair loss.
August 2024 in “International Journal of Molecular Sciences” Mesenchymal Stem Cell therapy shows promise for treating hair loss in Alopecia Areata.
1 citations
,
January 2025 in “Genes & Diseases” Understanding T cells and signaling pathways can lead to better treatments for hair loss.
71 citations
,
October 2013 in “Experimental Dermatology” Vitiligo and alopecia areata may have similar causes despite their differences.
45 citations
,
June 2018 in “Frontiers in immunology” MDSC-Exo can treat autoimmune alopecia areata and promote hair regrowth in mice.
36 citations
,
June 2015 in “International journal of toxicology” Trichloroethylene causes skin inflammation in mice by increasing certain immune proteins.
4 citations
,
August 2024 in “Skin Research and Technology” The study was retracted.
1 citations
,
September 2025 in “Frontiers in Immunology” Alopecia areata involves complex immune dysregulation, mainly driven by Th1 activity, suggesting broader treatment strategies.
Certain immune markers and vitamin levels could help diagnose alopecia areata.
February 2024 in “Veterinary sciences” Canine pemphigus foliaceus involves significant immune activity and shares similarities with human pemphigus.
January 2020 in “Archives of Medicine and Health Sciences” Certain immune molecules and stress affect hair loss, and while genes play a role, more research is needed to fully understand and treat it.
97 citations
,
May 2019 in “Frontiers in Cell and Developmental Biology” Abnormal ECM and immune cell interactions can cause skin diseases.
37 citations
,
December 2001 in “Journal of Investigative Dermatology” Leptin may play a role in hair growth and hair follicle health.
26 citations
,
June 2024 in “Frontiers in Immunology” SOCS1 and SOCS3 help control skin inflammation and are important for developing treatments for skin diseases.
24 citations
,
July 2021 in “Pharmaceutics” Ruxolitinib cream effectively targets and treats inflammatory skin diseases.
22 citations
,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.